Overview

* LeMaitre Vascular Inc ( LMAT ) Q2 sales rise 15% yr/yr, beating analyst expectations

* EPS for Q2 up 16%, driven by higher sales and gross margin

* Co raises 2025 guidance, reflecting confidence in sales and profit growth

Outlook

* LeMaitre sees Q3 sales $61.2 mln to $63.2 mln

* Company expects full-year sales $248 mln to $254 mln

* LeMaitre projects Q3 EPS $0.54 to $0.59

* Company anticipates full-year EPS $2.23 to $2.37

Result Drivers

* CATHETERS AND GRAFTS - Catheters and grafts drove Q2 sales growth, increasing by 27% and 19% respectively

* REGIONAL SALES GROWTH - EMEA sales increased by 23%, while Americas and APAC both grew by 12%

* HIGHER SELLING PRICES - Gross margin improved to 70.0% due to higher average selling prices and manufacturing efficiencies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $64.23 $62.50

mln mln (10

Analysts

)

Q2 Net $13.78

Income mln

Q2 Gross $44.97

Profit mln

Q2 $16.14

Income mln

From

Operatio

ns

Q2 $18.07

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for LeMaitre Vascular Inc ( LMAT ) is $108.00, about 21.9% above its August 4 closing price of $84.36

* The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 39 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)